Recent clinical trials with blocking antibodies for the immune checkpoint molecule programmed cell death protein 1 (PD-1) have shown to improve survival in patients with advanced head and neck squamous cell carcinoma [11,12,13]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.